Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: An observational study
BMC Cardiovascular Disorders Jan 22, 2019
Cosentino ER, et al. – Researchers investigated whether indacaterol/glycopyrronium therapy is a safe and efficacious treatment option for patients (n=56) with a history of heart failure (HF; New York Heart Association classes II and III) and stable chronic obstructive pulmonary disease (COPD). At baseline, as well as 6 months after therapy, participant blood samples, clinical assessment, echocardiograms and basal spirometry were assessed. Findings demonstrated that this therapy was well-tolerated and effective. Compared with baseline, a significant reduction in brain natriuretic peptide levels was noted after 6 months of treatment, as well as improved clinical status in a higher percentage of patients. Also, significant improvements were evident in all respiratory parameters (forced expiratory volume in 1 s [FEV1], FEV1/forced vital capacity ratio, and COPD Assessment Test scores). There were no hospitalizations owing to HF or COPD exacerbation. Death attributed to respiratory failure was reported for one patient.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries